Tri-Long Nguyen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tri-Long Nguyen has a total of 158 co-authors. Here are the top co-authors by number of shared publications:
- Gary Stephen Collins
Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
7 shared publications - Thomas Paul Alfons Debray
Julius Center for Health Sciences and Primary Care University Medical Center Utrecht, Utrecht University Utrecht The Netherlands
7 shared publications - Jessica Spence
Department of Anesthesia, McMaster University, Hamilton, ON, Canada; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada; Population Health Research Institute, Hamilton, ON, Canada; World Health Research Trust, Hamilton, ON, Canada; Division of Critical Care, Department of Medicine, McMaster University, Hamilton, ON, Canada
6 shared publications Paul Landais
6 shared publications- Géraldine Leguelinel-Blache
Department of Pharmacy, Nimes University Hospital, University of Montpellier, Nimes, France
5 shared publications - Paul Landais
Clinical Research Institute, Montpellier University, France
5 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (9) , 101934
Everolimus and de novo malignancies after liver transplantation: a Nationwide Emulated Trial Using Real-World Data
- 8 July 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (9) , 101934
Open AccessEverolimus and de novo malignancies after liver transplantation: a Nationwide Emulated Trial Using Real-World Data
- Open Access
- 26 March 2026
- Published by Elsevier in SSRN Electronic Journal
Everolimus and the Recurrence of Hepatocellular Carcinoma after liver transplantation: A Nationwide Emulated Target Trial Based on Real-World Data
Background: Hepatocellular carcinoma (HCC) is a major indication for liver transplantation (LT). Post-transplant recurrence affects approximately 15% of patients. Everolimus (EVR), an mTOR inhibitor, can reduce recurrence through antitumor effects; however, supporting data remain heterogeneous. Objective: To evaluate the association between EVR use and HCC recurrence following LT for HCC. Methods: Emulated target trials were conducted using French nationwide administrative health data. The cloning–censoring–weighting approach was applied to estimate the effects of EVR initiation and discontinuation after initiation. The primary outcome was the cumulative incidence of HCC recurrence. The secondary outcome was overall survival. Results: Between 2009 and 2020, 3,670 patients underwent LT for HCC, 958 of whom (26.1%) initiated everolimus within three years of LT. The 5-year HCC recurrence rate was 12.5%. Everolimus initiation within three years of LT was associated with lower HCC recurrence at 5 years (HR 0.75; 95% CI 0.64–0.91) and 10 years (HR 0.77; 95% CI 0.61–0.95) and improved 5-year survival (HR 0.92; 95% CI 0.88–0.94). Among everolimus users, discontinuation increased the HCC recurrence risk at 5 years (HR 1.83; 95% CI 1.77–1.93) and 10 years (HR 1.51; 95% CI 1.29–1.71), with reduced survival at both time points (5 years: HR 1.63; 95% CI 1.55–1.87; 10 years: HR 1.63; 95% CI 1.55–1.87). Everolimus initiation 1 year pre-recurrence improved post-recurrence survival (HR 0.64; 95% CI 0.47–0.87; p = 0.005). Conclusion: Everolimus use after LT for HCC reduces the risk of recurrence and improves survival. Discontinuation increases the risks of recurrence and mortality. These findings support the use of everolimus as a key component of immunosuppression in HCC transplant patients, emphasizing the importance of treatment continuity.
- 26 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessEverolimus and the Recurrence of Hepatocellular Carcinoma after liver transplantation: A Nationwide Emulated Target Trial Based on Real-World Data
Background: Hepatocellular carcinoma (HCC) is a major indication for liver transplantation (LT). Post-transplant recurrence affects approximately 15% of patients. Everolimus (EVR), an mTOR inhibitor, can reduce recurrence through antitumor effects; however, supporting data remain heterogeneous. Objective: To evaluate the association between EVR use and HCC recurrence following LT for HCC. Methods: Emulated target trials were conducted using French nationwide administrative health data. The cloning–censoring–weighting approach was applied to estimate the effects of EVR initiation and discontinuation after initiation. The primary outcome was the cumulative incidence of HCC recurrence. The secondary outcome was overall survival. Results: Between 2009 and 2020, 3,670 patients underwent LT for HCC, 958 of whom (26.1%) initiated everolimus within three years of LT. The 5-year HCC recurrence rate was 12.5%. Everolimus initiation within three years of LT was associated with lower HCC recurrence at 5 years (HR 0.75; 95% CI 0.64–0.91) and 10 years (HR 0.77; 95% CI 0.61–0.95) and improved 5-year survival (HR 0.92; 95% CI 0.88–0.94). Among everolimus users, discontinuation increased the HCC recurrence risk at 5 years (HR 1.83; 95% CI 1.77–1.93) and 10 years (HR 1.51; 95% CI 1.29–1.71), with reduced survival at both time points (5 years: HR 1.63; 95% CI 1.55–1.87; 10 years: HR 1.63; 95% CI 1.55–1.87). Everolimus initiation 1 year pre-recurrence improved post-recurrence survival (HR 0.64; 95% CI 0.47–0.87; p = 0.005). Conclusion: Everolimus use after LT for HCC reduces the risk of recurrence and improves survival. Discontinuation increases the risks of recurrence and mortality. These findings support the use of everolimus as a key component of immunosuppression in HCC transplant patients, emphasizing the importance of treatment continuity.
- Open Access
- 24 September 2025
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 40 (11) , 1369-1379
Sex, male origin microchimerism, and mortality in a Danish cohort
We previously demonstrated that women with detectable male cells in peripheral blood – male origin microchimerism (a presumed souvenir from pregnancy) – enjoy half the risk of all-cause mortality compared with women tested negative. However, such differences are vulnerable to confounding. Also, it is unknown whether better survival in women vs. men is confined to women testing male origin microchimerism positive. In this updated analysis, we first compared the survival of positive and negative women using prognostic score weighing to minimize potential confounding. Next, we compared the survival of women tested positive and negative for male origin microchimerism to men. Women ( n = 766) and men ( n = 1,000) from the Diet, Cancer, and Health cohort aged 50–64 years in 1993–1997 were followed until 2017 for all-cause mortality in national Danish registers. Based on predictors of death, we calculated prognostic scores for all women and compared mortality according to male origin microchimerism status by prognostic score weighted Cox regression adjusting for potential confounding. Next, we compared mortality across positive/negative women and men. Women who tested male origin microchimerism positive versus negative had a 50% lower mortality rate (adjusted HR = 0.50 [95% CI 0.32–0.77]). Compared with men, women who tested positive had a 51% lower mortality rate (HR = 0.49 [95% confidence interval (CI) 0.38–0.61]), whereas women who tested negative had a similar rate (HR = 0.83 [95% CI 0.63–1.09]). Women who tested positive for male origin microchimerism lived longer than their counterparts who tested negative, who appeared to have a similar survival pattern to that of men.
- 24 September 2025
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 40 (11) , 1369-1379
Open AccessSex, male origin microchimerism, and mortality in a Danish cohort
We previously demonstrated that women with detectable male cells in peripheral blood – male origin microchimerism (a presumed souvenir from pregnancy) – enjoy half the risk of all-cause mortality compared with women tested negative. However, such differences are vulnerable to confounding. Also, it is unknown whether better survival in women vs. men is confined to women testing male origin microchimerism positive. In this updated analysis, we first compared the survival of positive and negative women using prognostic score weighing to minimize potential confounding. Next, we compared the survival of women tested positive and negative for male origin microchimerism to men. Women ( n = 766) and men ( n = 1,000) from the Diet, Cancer, and Health cohort aged 50–64 years in 1993–1997 were followed until 2017 for all-cause mortality in national Danish registers. Based on predictors of death, we calculated prognostic scores for all women and compared mortality according to male origin microchimerism status by prognostic score weighted Cox regression adjusting for potential confounding. Next, we compared mortality across positive/negative women and men. Women who tested male origin microchimerism positive versus negative had a 50% lower mortality rate (adjusted HR = 0.50 [95% CI 0.32–0.77]). Compared with men, women who tested positive had a 51% lower mortality rate (HR = 0.49 [95% confidence interval (CI) 0.38–0.61]), whereas women who tested negative had a similar rate (HR = 0.83 [95% CI 0.63–1.09]). Women who tested positive for male origin microchimerism lived longer than their counterparts who tested negative, who appeared to have a similar survival pattern to that of men.
- Open Access
- 17 April 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 1-4
Kindness as a public health action
The current global mental health crisis needs action. Here we show, using empirical evidence of randomised controlled trials combined with Rose’s theoretical framework of preventive medicine and epidemiological principles, that the universal practice of kindness is a potentially effective grassroots public health promotion action that could propagate from the individual to the collective. Beyond effectiveness alone, we present medical ethics principles to show that the universal practice of kindness is also relatively costless, socially just, inherently consensual, empowering, and immediately available to, for and within every one of us. We argue that the need for structural changes and future research studies should not justify delaying the individual practice of kindness in our daily lives, since kindness is compatible with research, clinical practice and policy-making.
- 17 April 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 1-4
Open AccessKindness as a public health action
The current global mental health crisis needs action. Here we show, using empirical evidence of randomised controlled trials combined with Rose’s theoretical framework of preventive medicine and epidemiological principles, that the universal practice of kindness is a potentially effective grassroots public health promotion action that could propagate from the individual to the collective. Beyond effectiveness alone, we present medical ethics principles to show that the universal practice of kindness is also relatively costless, socially just, inherently consensual, empowering, and immediately available to, for and within every one of us. We argue that the need for structural changes and future research studies should not justify delaying the individual practice of kindness in our daily lives, since kindness is compatible with research, clinical practice and policy-making.
- Open Access
- 1 August 2024
- Published by Wiley in Statistics in Medicine
- Vol. 43 (23) , 4481-4498
Evaluating individualized treatment effect predictions: A model‐based perspective on discrimination and calibration assessment
In recent years, there has been a growing interest in the prediction of individualized treatment effects. While there is a rapidly growing literature on the development of such models, there is little literature on the evaluation of their performance. In this paper, we aim to facilitate the validation of prediction models for individualized treatment effects. The estimands of interest are defined based on the potential outcomes framework, which facilitates a comparison of existing and novel measures. In particular, we examine existing measures of discrimination for benefit (variations of the c‐for‐benefit), and propose model‐based extensions to the treatment effect setting for discrimination and calibration metrics that have a strong basis in outcome risk prediction. The main focus is on randomized trial data with binary endpoints and on models that provide individualized treatment effect predictions and potential outcome predictions. We use simulated data to provide insight into the characteristics of the examined discrimination and calibration statistics under consideration, and further illustrate all methods in a trial of acute ischemic stroke treatment. The results show that the proposed model‐based statistics had the best characteristics in terms of bias and accuracy. While resampling methods adjusted for the optimism of performance estimates in the development data, they had a high variance across replications that limited their accuracy. Therefore, individualized treatment effect models are best validated in independent data. To aid implementation, a software implementation of the proposed methods was made available in R.
- 1 August 2024
- Published by Wiley in Statistics in Medicine
- Vol. 43 (23) , 4481-4498
Open AccessEvaluating individualized treatment effect predictions: A model‐based perspective on discrimination and calibration assessment
In recent years, there has been a growing interest in the prediction of individualized treatment effects. While there is a rapidly growing literature on the development of such models, there is little literature on the evaluation of their performance. In this paper, we aim to facilitate the validation of prediction models for individualized treatment effects. The estimands of interest are defined based on the potential outcomes framework, which facilitates a comparison of existing and novel measures. In particular, we examine existing measures of discrimination for benefit (variations of the c‐for‐benefit), and propose model‐based extensions to the treatment effect setting for discrimination and calibration metrics that have a strong basis in outcome risk prediction. The main focus is on randomized trial data with binary endpoints and on models that provide individualized treatment effect predictions and potential outcome predictions. We use simulated data to provide insight into the characteristics of the examined discrimination and calibration statistics under consideration, and further illustrate all methods in a trial of acute ischemic stroke treatment. The results show that the proposed model‐based statistics had the best characteristics in terms of bias and accuracy. While resampling methods adjusted for the optimism of performance estimates in the development data, they had a high variance across replications that limited their accuracy. Therefore, individualized treatment effect models are best validated in independent data. To aid implementation, a software implementation of the proposed methods was made available in R.
- Open Access
- 22 May 2024
- Published by Taylor & Francis in Journal of Communication in Healthcare
- Vol. 17 (3) , 236-238
Opportunities for public health engagement with citizens in neighbourhood art spaces: the modern agora
- 22 May 2024
- Published by Taylor & Francis in Journal of Communication in Healthcare
- Vol. 17 (3) , 236-238
Open AccessOpportunities for public health engagement with citizens in neighbourhood art spaces: the modern agora
- 12 December 2023
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 31 (8) , 945-953
The potential benefit of statin prescription based on prediction of treatment responsiveness in older individuals: an application to the PROSPER randomized controlled trial
Aims: Clinical guidelines often recommend treating individuals based on their cardiovascular risk. We revisit this paradigm and quantify the efficacy of three treatment strategies: (i) overall prescription, i.e. treatment to all individuals sharing the eligibility criteria of a trial; (ii) risk-stratified prescription, i.e. treatment only to those at an elevated outcome risk; and (iii) prescription based on predicted treatment responsiveness. Methods and results: We reanalysed the PROSPER randomized controlled trial, which included individuals aged 70–82 years with a history of, or risk factors for, vascular diseases. We conducted the derivation and internal–external validation of a model predicting treatment responsiveness. We compared with placebo (n = 2913): (i) pravastatin (n = 2891); (ii) pravastatin in the presence of previous vascular diseases and placebo in the absence thereof (n = 2925); and (iii) pravastatin in the presence of a favourable prediction of treatment response and placebo in the absence thereof (n = 2890). We found an absolute difference in primary outcome events composed of coronary death, non-fatal myocardial infarction, and fatal or non-fatal stroke, per 10 000 person-years equal to: −78 events (95% CI, −144 to −12) when prescribing pravastatin to all participants; −66 events (95% CI, −114 to −18) when treating only individuals with an elevated vascular risk; and −103 events (95% CI, −162 to −44) when restricting pravastatin to individuals with a favourable prediction of treatment response. Conclusion: Pravastatin prescription based on predicted responsiveness may have an encouraging potential for cardiovascular prevention. Further external validation of our results and clinical experiments are needed. Trial registration: ISRCTN40976937.
- 12 December 2023
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 31 (8) , 945-953
The potential benefit of statin prescription based on prediction of treatment responsiveness in older individuals: an application to the PROSPER randomized controlled trial
Aims: Clinical guidelines often recommend treating individuals based on their cardiovascular risk. We revisit this paradigm and quantify the efficacy of three treatment strategies: (i) overall prescription, i.e. treatment to all individuals sharing the eligibility criteria of a trial; (ii) risk-stratified prescription, i.e. treatment only to those at an elevated outcome risk; and (iii) prescription based on predicted treatment responsiveness. Methods and results: We reanalysed the PROSPER randomized controlled trial, which included individuals aged 70–82 years with a history of, or risk factors for, vascular diseases. We conducted the derivation and internal–external validation of a model predicting treatment responsiveness. We compared with placebo (n = 2913): (i) pravastatin (n = 2891); (ii) pravastatin in the presence of previous vascular diseases and placebo in the absence thereof (n = 2925); and (iii) pravastatin in the presence of a favourable prediction of treatment response and placebo in the absence thereof (n = 2890). We found an absolute difference in primary outcome events composed of coronary death, non-fatal myocardial infarction, and fatal or non-fatal stroke, per 10 000 person-years equal to: −78 events (95% CI, −144 to −12) when prescribing pravastatin to all participants; −66 events (95% CI, −114 to −18) when treating only individuals with an elevated vascular risk; and −103 events (95% CI, −162 to −44) when restricting pravastatin to individuals with a favourable prediction of treatment response. Conclusion: Pravastatin prescription based on predicted responsiveness may have an encouraging potential for cardiovascular prevention. Further external validation of our results and clinical experiments are needed. Trial registration: ISRCTN40976937.
- 11 October 2023
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 193 (2) , 377-388
Confounder Adjustment Using the Disease Risk Score: A Proposal for Weighting Methods
Propensity score analysis is a common approach to addressing confounding in nonrandomized studies. Its implementation, however, requires important assumptions (e.g., positivity). The disease risk score (DRS) is an alternative confounding score that can relax some of these assumptions. Like the propensity score, the DRS summarizes multiple confounders into a single score, on which conditioning by matching allows the estimation of causal effects. However, matching relies on arbitrary choices for pruning out data (e.g., matching ratio, algorithm, and caliper width) and may be computationally demanding. Alternatively, weighting methods, common in propensity score analysis, are easy to implement and may entail fewer choices, yet none have been developed for the DRS. Here we present 2 weighting approaches: One derives directly from inverse probability weighting; the other, named target distribution weighting, relates to importance sampling. We empirically show that inverse probability weighting and target distribution weighting display performance comparable to matching techniques in terms of bias but outperform them in terms of efficiency (mean squared error) and computational speed (up to >870 times faster in an illustrative study). We illustrate implementation of the methods in 2 case studies where we investigate placebo treatments for multiple sclerosis and administration of aspirin in stroke patients.
- 11 October 2023
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 193 (2) , 377-388
Confounder Adjustment Using the Disease Risk Score: A Proposal for Weighting Methods
Propensity score analysis is a common approach to addressing confounding in nonrandomized studies. Its implementation, however, requires important assumptions (e.g., positivity). The disease risk score (DRS) is an alternative confounding score that can relax some of these assumptions. Like the propensity score, the DRS summarizes multiple confounders into a single score, on which conditioning by matching allows the estimation of causal effects. However, matching relies on arbitrary choices for pruning out data (e.g., matching ratio, algorithm, and caliper width) and may be computationally demanding. Alternatively, weighting methods, common in propensity score analysis, are easy to implement and may entail fewer choices, yet none have been developed for the DRS. Here we present 2 weighting approaches: One derives directly from inverse probability weighting; the other, named target distribution weighting, relates to importance sampling. We empirically show that inverse probability weighting and target distribution weighting display performance comparable to matching techniques in terms of bias but outperform them in terms of efficiency (mean squared error) and computational speed (up to >870 times faster in an illustrative study). We illustrate implementation of the methods in 2 case studies where we investigate placebo treatments for multiple sclerosis and administration of aspirin in stroke patients.
- Open Access
- 13 June 2023
- Published by Wiley in Statistics in Medicine
- Vol. 42 (19) , 3508-3528
Propensity‐based standardization to enhance the validation and interpretation of prediction model discrimination for a target population
External validation of the discriminative ability of prediction models is of key importance. However, the interpretation of such evaluations is challenging, as the ability to discriminate depends on both the sample characteristics (ie, case‐mix) and the generalizability of predictor coefficients, but most discrimination indices do not provide any insight into their respective contributions. To disentangle differences in discriminative ability across external validation samples due to a lack of model generalizability from differences in sample characteristics, we propose propensity‐weighted measures of discrimination. These weighted metrics, which are derived from propensity scores for sample membership, are standardized for case‐mix differences between the model development and validation samples, allowing for a fair comparison of discriminative ability in terms of model characteristics in a target population of interest. We illustrate our methods with the validation of eight prediction models for deep vein thrombosis in 12 external validation data sets and assess our methods in a simulation study. In the illustrative example, propensity score standardization reduced between‐study heterogeneity of discrimination, indicating that between‐study variability was partially attributable to case‐mix. The simulation study showed that only flexible propensity‐score methods (allowing for non‐linear effects) produced unbiased estimates of model discrimination in the target population, and only when the positivity assumption was met. Propensity score‐based standardization may facilitate the interpretation of (heterogeneity in) discriminative ability of a prediction model as observed across multiple studies, and may guide model updating strategies for a particular target population. Careful propensity score modeling with attention for non‐linear relations is recommended.
- 13 June 2023
- Published by Wiley in Statistics in Medicine
- Vol. 42 (19) , 3508-3528
Open AccessPropensity‐based standardization to enhance the validation and interpretation of prediction model discrimination for a target population
External validation of the discriminative ability of prediction models is of key importance. However, the interpretation of such evaluations is challenging, as the ability to discriminate depends on both the sample characteristics (ie, case‐mix) and the generalizability of predictor coefficients, but most discrimination indices do not provide any insight into their respective contributions. To disentangle differences in discriminative ability across external validation samples due to a lack of model generalizability from differences in sample characteristics, we propose propensity‐weighted measures of discrimination. These weighted metrics, which are derived from propensity scores for sample membership, are standardized for case‐mix differences between the model development and validation samples, allowing for a fair comparison of discriminative ability in terms of model characteristics in a target population of interest. We illustrate our methods with the validation of eight prediction models for deep vein thrombosis in 12 external validation data sets and assess our methods in a simulation study. In the illustrative example, propensity score standardization reduced between‐study heterogeneity of discrimination, indicating that between‐study variability was partially attributable to case‐mix. The simulation study showed that only flexible propensity‐score methods (allowing for non‐linear effects) produced unbiased estimates of model discrimination in the target population, and only when the positivity assumption was met. Propensity score‐based standardization may facilitate the interpretation of (heterogeneity in) discriminative ability of a prediction model as observed across multiple studies, and may guide model updating strategies for a particular target population. Careful propensity score modeling with attention for non‐linear relations is recommended.
- Open Access
- 17 May 2023
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 3 (5) , e0001556
Assessing racial bias in type 2 diabetes risk prediction algorithms
Risk prediction models for type 2 diabetes can be useful for the early detection of individuals at high risk. However, models may also bias clinical decision-making processes, for instance by differential risk miscalibration across racial groups. We investigated whether the Prediabetes Risk Test (PRT) issued by the National Diabetes Prevention Program, and two prognostic models, the Framingham Offspring Risk Score, and the ARIC Model, demonstrate racial bias between non-Hispanic Whites and non-Hispanic Blacks. We used National Health and Nutrition Examination Survey (NHANES) data, sampled in six independent two-year batches between 1999 and 2010. A total of 9,987 adults without a prior diagnosis of diabetes and with fasting blood samples available were included. We calculated race- and year-specific average predicted risks of type 2 diabetes according to the risk models. We compared the predicted risks with observed ones extracted from the US Diabetes Surveillance System across racial groups (summary calibration). All investigated models were found to be miscalibrated with regard to race, consistently across the survey years. The Framingham Offspring Risk Score overestimated type 2 diabetes risk for non-Hispanic Whites and underestimated risk for non-Hispanic Blacks. The PRT and the ARIC models overestimated risk for both races, but more so for non-Hispanic Whites. These landmark models overestimated the risk of type 2 diabetes for non-Hispanic Whites more severely than for non-Hispanic Blacks. This may result in a larger proportion of non-Hispanic Whites being prioritized for preventive interventions, but it also increases the risk of overdiagnosis and overtreatment in this group. On the other hand, a larger proportion of non-Hispanic Blacks may be potentially underprioritized and undertreated.
- 17 May 2023
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 3 (5) , e0001556
Open AccessAssessing racial bias in type 2 diabetes risk prediction algorithms
Risk prediction models for type 2 diabetes can be useful for the early detection of individuals at high risk. However, models may also bias clinical decision-making processes, for instance by differential risk miscalibration across racial groups. We investigated whether the Prediabetes Risk Test (PRT) issued by the National Diabetes Prevention Program, and two prognostic models, the Framingham Offspring Risk Score, and the ARIC Model, demonstrate racial bias between non-Hispanic Whites and non-Hispanic Blacks. We used National Health and Nutrition Examination Survey (NHANES) data, sampled in six independent two-year batches between 1999 and 2010. A total of 9,987 adults without a prior diagnosis of diabetes and with fasting blood samples available were included. We calculated race- and year-specific average predicted risks of type 2 diabetes according to the risk models. We compared the predicted risks with observed ones extracted from the US Diabetes Surveillance System across racial groups (summary calibration). All investigated models were found to be miscalibrated with regard to race, consistently across the survey years. The Framingham Offspring Risk Score overestimated type 2 diabetes risk for non-Hispanic Whites and underestimated risk for non-Hispanic Blacks. The PRT and the ARIC models overestimated risk for both races, but more so for non-Hispanic Whites. These landmark models overestimated the risk of type 2 diabetes for non-Hispanic Whites more severely than for non-Hispanic Blacks. This may result in a larger proportion of non-Hispanic Whites being prioritized for preventive interventions, but it also increases the risk of overdiagnosis and overtreatment in this group. On the other hand, a larger proportion of non-Hispanic Blacks may be potentially underprioritized and undertreated.